Carpe Diem

Tag: Short Interest

Kodiak Sciences KOD FunStock dashboard tracking institutional ownership, short interest, financials and Phase 3 biotech results.

Kodiak Sciences (KOD): Why the FunStock Gauges Keep Running After You Buy

Kodiak Sciences was around $26 when we published our cautiously bullish analysis after Baker Bros. made a major investment. Nine months later, KOD closed at $89.92 after successful Phase 3 results. But the bigger lesson may be what the FunStock gauges revealed along the way.

Read entire article

Tags: Baker Bros Advisors, Baker Brothers, biotech investing, biotech stocks, Carpe Diem, FDA approval, FunStock, FunStock Method, growth stocks, hedge funds, insider investing, institutional ownership, investment research, KOD, KOD stock, Kodiak Sciences, Kodiak Sciences stock, KSI-501, Phase 3 clinical trials, retinal disease, short interest, short squeeze, speculative investing, tabirafusp-ted, wet AMD, Zenkuda
Illustration showing Moderna stock surging on one side and hedge fund shorts hiding in bushes on the other, representing contrasting market positions and short interest in major S&P stocks.

No Bulls? Just Bushes. 🌳🐻

Moderna just doubled on your earlier call — even as hedge funds pile into big shorts. Here’s the most shorted stocks in the S&P 500 and how to think about it.

Read entire article

Tags: Carpe Diem, CHTR, contrarian investing, DVA, funanc1al edge, FUNanc1al humor, funanc1al investing, FUNanc1al Momentum, Hedge Funds, Lennar Corp, Moderna, MRNA Bullish, S&P 500 Shorts, Short Interest, SMCI, Stock Market Humor, Stocks Volatility, top shorted stocks, TTD